Psychedelic research timeline
Peripartum: the psychedelic research timeline
The peripartum record is small and heterogeneous: perioperative ketamine prevention studies, one terminated 5-MeO-DMT programme and the first dedicated short-acting psychedelic result. It should not be read as a mature treatment literature.
Milestones are editorially selected from Blossom’s research catalogue. Future markers are limited to important trials with dated public guidance and are shown as planned, not promised.
Hover any marker to preview its callout on the canvas, then click to pin it. Pinned is what stays open, fills this panel with the full context and links, and is what an export captures. Landmarks stay labelled on the canvas so the exported image reads on its own.
Download the artifact
Exports rasterise the live SVG, so whatever you have toggled is what you get.
Ketamine prevention studies
2017 to 2022Trials ask whether dosing around caesarean delivery can prevent postpartum depression.2017-03
ended earlyA single ketamine bolus does not prevent postpartum depression
A randomised, double-blind trial finds that one low ketamine dose during caesarean delivery does not prevent postpartum depression.
2022-04
Perioperative ketamine evidence is pooled
A meta-analysis combines single-dose ketamine studies around caesarean delivery. The question remains prevention after surgery, not psychedelic-assisted treatment.
Dedicated psychedelic programmes
2023 onwardsOne programme stops; another reports an early positive signal.2023-03
GH Research
ended earlyPostpartum depression (terminated)
A Phase II in postpartum depression is terminated. The results were still published in 2026.
Terminated trials usually vanish. Nobody publishes them, so the field never learns what went wrong, and the same idea gets tried again by someone else.
This one did not vanish. The Phase 2a results were published in the Journal of Clinical Psychiatry in June 2026, three years after the trial stopped. Both events sit on this canvas because both are true, and a timeline that showed only the successes would be marketing rather than evidence.
Termination is also not the same as failure. Trials stop for recruitment problems, funding, or strategic reprioritisation as often as for safety or futility, and the registry record rarely says which.
2025-08
Reunion Neuroscience
RE104 hits its endpoint in postpartum depression
A 23.0-point depression score reduction at day seven against 17.2 for the control arm, with an effect visible from day one.
Reunion Neuroscience reports positive topline results from RECONNECT, a Phase 2 of luvesilocin (RE104, a psilocin prodrug) in postpartum depression across 38 US sites. The 30 mg arm reached a 23.0-point reduction on the depression scale at day seven against 17.2 for the 1.5 mg control, with no serious adverse events reported.
Postpartum depression is a well-chosen indication. It affects roughly one in seven women after birth, it has an existing rapid-acting comparator in the approved neurosteroids, and the regulatory path is sympathetic. The FDA granted Breakthrough Therapy Designation in February 2026 and, after an end-of-phase-2 meeting, indicated that a single additional pivotal trial could support a filing.
The control arm is worth noticing. A 17.2-point improvement in the low-dose group is a large response to something intended as a comparator, which is the blinding problem showing up again in the numbers rather than in the discussion section.
2026-02
Low-dose esketamine after caesarean delivery reports
A study reports improved postpartum depression symptoms and recovery quality after a single low dose of esketamine in women undergoing caesarean section.
Peripartum
Postpartum depression studies at the edge of psychedelic development
Research Landscape
What the registered trials connected to Peripartum look like when you line them up. Counts come from Blossom’s trial records as of August 2026.
How fast is Peripartum research growing?
SourcedRegistered trials by recorded study-start year. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (18 of 18 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
What's live right now, and what stopped?
SourcedRegistry status of all 18 Peripartum trials Blossom tracks. Orange marks trials recruiting or opening.
- Recruiting or opening
- 317%
- Underway, not recruiting
- 16%
- Completed
- 844%
- Stopped early
- 317%
- Unknown / other
- 317%
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Which compounds carry the Peripartum research?
SourcedTrials per compound. Orange marks the most-studied compound.
Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.